Dose-related effects of direct hemoperfusion using a cytokine adsorbent column for the treatment of experimental endotoxemia

Intensive Care Med. 2007 Mar;33(3):529-33. doi: 10.1007/s00134-006-0471-4. Epub 2006 Dec 8.

Abstract

Objective: To clarify the dose-related effects of direct hemoperfusion using a cytokine adsorbent column (CTR) on the mortality and inflammatory responses to endotoxin-induced shock in rats.

Design: Prospective and randomized study.

Setting: University research laboratory.

Subjects: Male Wistar rats.

Interventions: Forty-eight rats were injected intravenously with Escherichia coli endotoxin (15 mg/kg over 2 min), and then were randomly allocated to one of the following four groups (n = 12 per group): control group, treated without CTR for 120 min; quarter-dose treatment group, treated with CTR 0.25 ml for 120 min; half-dose treatment group, treated with CTR 0.50 ml; and full-dose treatment group, treated with CTR 1.0 ml.

Measurements and results: Hemodynamics and arterial blood gases were recorded, and mortality and plasma cytokine concentrations were calculated for the 8-h observation period. The mortality rates 8 h after endotoxin injection were 92%, 58%, 42% and 17% for the control column, quarter-dose, half-dose, and full-dose CTR groups, respectively. The increases in plasma cytokine concentrations were smaller in the half-dose and full-dose CTR treatment groups than in the endotoxemic group.

Conclusions: The present study showed that CTR treatment dose-dependently decreased the mortality rate and inhibited inflammatory responses in vivo.

Publication types

  • Evaluation Study

MeSH terms

  • Analysis of Variance
  • Animals
  • Cytokines / blood*
  • Endotoxemia / blood
  • Endotoxemia / therapy*
  • Hemoperfusion / methods*
  • Interleukin-6
  • Male
  • Prospective Studies
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Shock, Septic / blood
  • Shock, Septic / therapy*
  • Survival Analysis
  • Tumor Necrosis Factor-alpha

Substances

  • Cytokines
  • Interleukin-6
  • Tumor Necrosis Factor-alpha